Selective tyrosine kinase inhibitors

Bibliography

• HANKS SK, HUNTER T: Protein kinases 6 - the eukary-otic protein kinase superfamily kinase (catalytic) domain structure and classification. FASEB J (1995) 9(8)576–596.
   PubMed Web of Science ®Google Scholar
• GIBBS JB: Mechanism-based target identification anddrug discovery in cancer research. Science (2000) 287:1969–1973.
   PubMed Web of Science ®Google Scholar
• GREENLEE RT, MURRAY T, BOLDEN S, WINGO PA: Cancer Statistics, 2000. CA Cariced Clin. (2000) 50:7–33.
   PubMed Web of Science ®Google Scholar
• BRIDGES AJ: Current progress towards the develop-ment of tyrosine kinase inhibitors as anticancer agents. Emerging Drugs (1998) 3:279–292.
   Google Scholar
• WEBSTER KR, KIMBALL SD: Novel drugs targeting thecell cycle. Emerging Drugs (2000) 5(0:45–59.
   Google Scholar
• MODJTAHEDI M, DEAN C: The receptor for EGF and its ligands: Expression, prognostic value and target for therapy in cancer. Int. J Oncol. (1994) 4:277–296.
   PubMed Web of Science ®Google Scholar
• BISCARDI JS, TICE DA, PARSONS SJ: c-src, receptor tyrosine kinases and human cancer. Adv. Cancer Res. (1999) 76:61–119.
   PubMed Web of Science ®Google Scholar
• SEPP-LORENZINO L, PAN B: Angiogenesis - research frontiers. A basic science conference of the New York Academy of Medicine January 10th 2000, New York, USA. Exp. Opin. Invest. Drugs (2000) 0(0929–935.
   Google Scholar
• NICOSIA RF: Endogenous regulation of angiogenesis in vitro. NATO ASI Ser. Ser. A (1998) 208 (Angiogene-sis):285–296.
   Google Scholar
• LAFUENTE JV, ADAN B, ALKIZA K, GARIBI JM, ROSSI M, CRUZ-SANCHEZ FF: Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-beta) in human gliomas. J. Mot. Neurosci. (1999) 13 (1-2) :177–185.
   PubMed Web of Science ®Google Scholar
• BEN-NERIAH Y, DALEY GQ, MES-MASSON A-M, WITTE ON, BALTIMORE D: The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science (1986) 233:212–214.
   PubMed Web of Science ®Google Scholar
• TURNER M, SCHVVEIGHOFFER E, COLUCCI F, DI SANTO JP, TYBULEWICZ VL: Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunology Today (2000) 21 (3):148–154.
   PubMedGoogle Scholar
• CHAN AC, KADLECEK TA, ELDER ME, et al.: ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency. Science (1994) 264:1599–1601.
   PubMed Web of Science ®Google Scholar
• ROIFMAN CM: Selection transduction defect (STD) dueto Zap-70 kinase deficiency. Immunodeficiency (1995) 5(3):193–211.
   PubMedGoogle Scholar
• GOLDMAN FD, BALLAS ZK, SCHUTTE BC, et al.: Defective expression of p561ck in an infant with severe combined immunodeficiency. J Clin. Invest. (1998) 102 (2):421–429.
   PubMed Web of Science ®Google Scholar
• LIU KD, GAFFEN SL, GOLDSMITH MA: JAK/STAT signal-ling by cytokine receptors. CUIT. Opin. Immunol. (1998) 10: 271–278.
   Google Scholar
• SUDBECK EA, UCKUN FM: Recent advances in JAK3 kinase inhibitors. IDrugs (1999) 2:1026–1030.
   PubMedGoogle Scholar
• KUROSAKI T: Genetic analysis of B cell antigenreceptor signalling. Ann. Rev. Immunol. (1999) 17:555–592.
   PubMed Web of Science ®Google Scholar
• WOODBURN JR: An epidermal growth factor tyrosine kinase inhibitor selected for clinical development. J Immunother. (1997) 20(5):408.
   Google Scholar
• SMAILL JB, REWCASTLE GW, LOO JA, et al: Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermalgrowthfactorreceptor:4-(phenylamino)quinazoline- and 4-(phenylamino) pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med. Chem. (2000) 43:1380–1397.
   PubMed Web of Science ®Google Scholar
• MOYER JD, BARBACCI EG, IWATA KK, et al.: Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. (1997) 57 (20:4838–4848.
   PubMed Web of Science ®Google Scholar
• TRAXLER P, et al.: Preclinical profile of PKI166 - a novel and potent EGFR tyrosine kinase inhibitor for clinical development. Clin. Cancer Res. (1999) 5 (11):3750s.
   Google Scholar
• SUN L, TRAN N, HANG C, et al: Design, synthesis and evaluations of substituted 3-[(3- or 4-Carboxyethylpyrrol-2-y1) methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF and PDGF receptor tyrosine kinases. J Med. Chem. (1999) 42:5120–5130.
   PubMed Web of Science ®Google Scholar
• VAJKOCZY P, MENGER MD, VOLLMAR B, et al.: Inhibition of tumour growth, angiogenesis and microcirculation by the novel Flk-1 Inhibitor 5U5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia (1999) 1 (0 :31–41.
   PubMedGoogle Scholar
• SHAHEEN RM, DAVIS DW, LIU W et al: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. (1999) 59(20:5412–5416.
   PubMedGoogle Scholar
• FOX RI, HERRMANN ML, FRANGOU CG, et al.: Mechanism of action for leflunomide in rheumatoid arthritis. Clin. Immunol. (1999) 93(3):198–208.
   PubMed Web of Science ®Google Scholar
• XU X, SHEN J, MALL JW, et al: In vitro and in vivo antitu-mour activity of a novel immunomodulatory drug, leflunomide. Mechanisms of action. Biochem. Pharmacol. (1999) 58(9):1405–1413.
   PubMed Web of Science ®Google Scholar
• PANEK RL, LU GH, DAHRING TK, et al.: In vitro biological characterization and anti-angiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. J. Pharmacol. Exp. Ther. (1998) 286 (1):569–577.
   PubMed Web of Science ®Google Scholar
• TRAXLER P: Tyrosine kinase inhibitors in cancer treatment (part II). Exp. Opin. Ther. Patents (1998) 8(12):1599–1625.
   Web of Science ®Google Scholar
• ZIMMERMAN J, BUCHDUNGER E, METT H, MEYER T, LYDON NB: Potent and selective inhibitors of the ABL-kinase: phenylaminopyrimidine (PAP) deriva-tives. Bioorg. Med. Chem. Lett. (1997) 7(2):187–192.
   Web of Science ®Google Scholar
• DRUKER BJ, LYDON NB: lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. j Clin. Invest. (2000) 105 (1):3–7.
   Google Scholar
• DRUKER BJ, et al.: Clinical efficacy and safety of an Ablspecific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia. Blood (1999) 94:368a.
   PubMed Web of Science ®Google Scholar
• KAUR G, SAUSVILLE EA: Altered physical state of p210bcr-abl in tyrphostin AG957-treated K562 cells. AntiCancer Drugs (1996) 7(8):815–824.
   PubMed Web of Science ®Google Scholar
• VASSILEV A, OZER Z, NAVARA C, MAHAJAN S, UCKUN FM: Bruton's tyrosine kinase (BTK) as an inhibitor of the Fas/CD95 death inducing signaling complex (DISC). J. Biol. Chem. (1999) 274(3):1646–1656.
   PubMed Web of Science ®Google Scholar
• SUDBECK EA, LIU XP, NARLA RK, et al.: Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing anti-leukemic agents. Clin. Cancer Res. (1999) 5(6):1569–1582.
   PubMed Web of Science ®Google Scholar
• SUDBECK EA, UCKUN FM: Recent advances in JAK3 kinase inhibitors. IDrugs (1999) 2(10):1026–1030. •
   PubMedGoogle Scholar
• UCKUN FM, EK O, LIU XP, CHEN CL: In vivo toxicity and pharmacokinetic features of the Janus kinase 3 inhibitor WH1-P131 [4-(4'hydroxypheny1)-amino-6,7 -dim eth o -x y quin az o lin e an. Cancer Res. (1999) 5 (10):2954–2962.
   Google Scholar
• BARVIAN MR, et al: Development of c-src selective 8H-pyrido (2,3-d)pyrimidin-7 -one tyrosine kinase inhibitors via parallel synthesis. Proceedings Of The American Association Of Cancer Research (1998) 39 89 Meet. Abs. 1201.
   Google Scholar
• BULLINGTON JL, CAMERON JC, DAVIS JE, et al.: The development of novel and selective p56" tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. (1998) 8(18)2489–2494.
   PubMed Web of Science ®Google Scholar
• LIU Y, BISHOP A, WITUCKI L, et al.: Structural basis for selective inhibition of Src family kinases by PP1. Chem. Biol. (1999) 6(9):671–678.
   PubMed Web of Science ®Google Scholar
• MOFFAT D, DAVIS P, HUTCHINGS M, et al: 4-Pyridin-5-y1-2-(3,4,5-trimethoxyphenylamino)pyrimidines: potent and selective inhibitors of ZAP 70. Bioorg. Med. Chem. Lett. (1999) 9(23)3351–3356.
   PubMed Web of Science ®Google Scholar